PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

Overview of attention for article published in Frontiers in immunology, March 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 3 X users

patent: 2 patents

Readers on

mendeley: 7 Mendeley

Summary X Patents

So far, Altmetric has seen 5 X posts from 3 X users, with an upper bound of 35,965 followers.

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. https://t.co/6jUcC6QLjX Frontiers in Immunology | Sec. Cancer Immunity and Immunotherapy | Volume 14 - 2023 | https://t.co/zDE137mJgF https://t.co/VYvZVLO9kM

11 Oct 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer: Recurrent disease emerges in the majorit…

23 Mar 2023

Reply Repost Favourite

New Research: PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer: Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting… https://t.co/7SbpH4zFik #im

22 Mar 2023

Reply Repost Favourite

⚠️PRAME- and CTCF-Like BORIS-reactive TCRs for the treatment of ovarian cancer. ⚡️https://t.co/e7EQt0AHpk https://t.co/dfztioxRNH

21 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.